CN110167928A - 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 - Google Patents

作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 Download PDF

Info

Publication number
CN110167928A
CN110167928A CN201780083358.7A CN201780083358A CN110167928A CN 110167928 A CN110167928 A CN 110167928A CN 201780083358 A CN201780083358 A CN 201780083358A CN 110167928 A CN110167928 A CN 110167928A
Authority
CN
China
Prior art keywords
alkyl
base
aryl
heteroaryl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780083358.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·格马其
M·山德森
D·凯斯勒
C·科芬克
M·R·内瑟顿
J·莱姆哈特
T·温伯格
M·霍夫曼
F·萨瓦雷斯
A·鲍姆
D·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN110167928A publication Critical patent/CN110167928A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
CN201780083358.7A 2016-12-22 2017-12-21 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 Pending CN110167928A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16206422 2016-12-22
EP16206422.4 2016-12-22
PCT/EP2017/084265 WO2018115380A1 (en) 2016-12-22 2017-12-21 Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors

Publications (1)

Publication Number Publication Date
CN110167928A true CN110167928A (zh) 2019-08-23

Family

ID=57777432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083358.7A Pending CN110167928A (zh) 2016-12-22 2017-12-21 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物

Country Status (5)

Country Link
US (2) US10898487B2 (enExample)
EP (2) EP3878850A1 (enExample)
JP (1) JP7219218B2 (enExample)
CN (1) CN110167928A (enExample)
WO (1) WO2018115380A1 (enExample)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112174891A (zh) * 2020-11-02 2021-01-05 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
WO2021203768A1 (zh) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
WO2021249519A1 (zh) * 2020-06-11 2021-12-16 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113801114A (zh) * 2020-06-11 2021-12-17 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN113912608A (zh) * 2020-07-10 2022-01-11 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022017519A1 (zh) * 2020-07-24 2022-01-27 南京明德新药研发有限公司 喹唑啉类化合物
WO2022017339A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
WO2022028506A1 (zh) * 2020-08-06 2022-02-10 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN114436976A (zh) * 2021-01-29 2022-05-06 石药集团中奇制药技术（石家庄）有限公司 一种新型喹唑啉类衍生物及其制备和应用
CN114524810A (zh) * 2020-11-21 2022-05-24 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114621231A (zh) * 2020-12-14 2022-06-14 杭州中美华东制药有限公司 一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
WO2022121813A1 (zh) * 2020-12-07 2022-06-16 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685487A (zh) * 2020-12-27 2022-07-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114685488A (zh) * 2020-12-31 2022-07-01 南京圣和药业股份有限公司 作为sos1抑制剂的化合物及其应用
WO2022143533A1 (zh) * 2020-12-30 2022-07-07 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
CN114746411A (zh) * 2019-11-29 2022-07-12 印度鲁宾有限公司 取代的三环化合物
WO2022148442A1 (zh) * 2021-01-07 2022-07-14 武汉人福创新药物研发中心有限公司 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
WO2022166592A1 (zh) * 2021-02-02 2022-08-11 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
WO2022166974A1 (zh) * 2021-02-08 2022-08-11 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN114907284A (zh) * 2021-02-10 2022-08-16 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2022170917A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
WO2022171184A1 (zh) * 2021-02-10 2022-08-18 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022170802A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022184116A1 (zh) * 2021-03-05 2022-09-09 江苏先声药业有限公司 新型sos1抑制剂及其制备方法和应用
CN115043817A (zh) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
WO2022199635A1 (zh) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 苄氨基喹唑啉类衍生物
WO2022199670A1 (zh) * 2021-03-26 2022-09-29 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
CN115215847A (zh) * 2021-04-16 2022-10-21 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
CN115246841A (zh) * 2021-09-14 2022-10-28 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115417868A (zh) * 2021-09-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2022258057A1 (en) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Compounds as anticancer agents
WO2022262691A1 (en) * 2021-06-17 2022-12-22 Beijing Innocare Pharma Tech Co., Ltd. Heterocyclic compounds as sos1 inhibitors
WO2022268209A1 (zh) * 2021-06-24 2022-12-29 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN115605476A (zh) * 2019-12-27 2023-01-13 鲁宾有限公司（In） 取代的三环化合物
WO2023001229A1 (zh) * 2021-07-23 2023-01-26 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途
CN115677824A (zh) * 2021-07-26 2023-02-03 中国科学院上海药物研究所 可诱导sos1蛋白质降解的化合物、制备方法和用途
CN115677601A (zh) * 2021-07-29 2023-02-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115697994A (zh) * 2020-06-10 2023-02-03 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
CN115677699A (zh) * 2021-07-23 2023-02-03 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2023030216A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途
CN115942936A (zh) * 2020-06-24 2023-04-07 勃林格殷格翰国际有限公司 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
CN116143708A (zh) * 2021-11-21 2023-05-23 四川汇宇制药股份有限公司 一种多取代苯并氮杂芳基衍生物及其用途
WO2023109929A1 (zh) 2021-12-17 2023-06-22 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN116425742A (zh) * 2019-11-08 2023-07-14 锐新医药公司 双环杂芳基化合物及其用途
CN116444447A (zh) * 2023-06-19 2023-07-18 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用
WO2023138526A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 含烯丙基的甲基吡啶并嘧啶化合物的晶型
WO2023143147A1 (zh) * 2022-01-28 2023-08-03 上海优理惠生医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN116546985A (zh) * 2021-01-28 2023-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
CN116648250A (zh) * 2020-12-22 2023-08-25 韩美药品株式会社 作为sos1抑制剂的新型喹唑啉衍生物及其用途
CN116768858A (zh) * 2022-03-15 2023-09-19 杭州中美华东制药有限公司 具有kras-sos1抑制或降解活性的嵌合化合物及其用途
CN117024404A (zh) * 2022-05-10 2023-11-10 四川汇宇制药股份有限公司 苯并吡啶衍生物及其用途
WO2023241414A1 (zh) * 2022-06-13 2023-12-21 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物
WO2024061353A1 (zh) * 2022-09-23 2024-03-28 南京明德新药研发有限公司 喹唑啉类化合物的晶型及其制备方法
CN119907792A (zh) * 2022-10-21 2025-04-29 领泰生物医药(绍兴)有限公司 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途
CN119907792B (en) * 2022-10-21 2025-12-09 领泰生物医药(绍兴)有限公司 Benzyl or thiophene methylene substituted aminoquinazoline derivatives and their use as SOS1 degradants

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458445B1 (en) 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3878850A1 (en) * 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018126192A1 (en) * 2016-12-30 2018-07-05 Children's Medical Center Corporation Map2k1 (mek1) as a therapeutic target for arteriovenous malformations and associated disorders
EP3601267A1 (en) * 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
EP3710439B1 (en) 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3728254T (lt) 2017-12-21 2023-05-10 Boehringer Ingelheim International Gmbh Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US20220274979A1 (en) * 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
WO2020118066A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
BR112021024532A2 (pt) * 2019-06-19 2022-05-24 Boehringer Ingelheim Int Terapia combinada anticâncer
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
JP7622043B2 (ja) 2019-08-29 2025-01-27 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
WO2023205701A1 (en) * 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
BR112022021734A2 (pt) 2020-04-28 2022-12-06 Basf Se Uso de compostos de fórmula i, métodos para combater fungos fitopatogênicos, compostos e composições agroquímicas
EP3903581A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors i
UA129898C2 (uk) 2020-04-28 2025-09-03 Басф Се ЗАСТОСУВАННЯ СПОЛУК СТРОБІЛУРИНОВОГО ТИПУ ДЛЯ БОРОТЬБИ З ФІТОПАТОГЕННИМИ ГРИБАМИ, ЯКІ МІСТЯТЬ АМІНОКИСЛОТНУ ЗАМІНУ F129L В МІТОХОНДРІАЛЬНОМУ БІЛКУ ЦИТОХРОМІ b, ЩО НАДАЄ СТІЙКОСТІ ДО Qo ІНГІБІТОРІВ ІІ
EP3903584A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iv
DK4142497T3 (da) 2020-04-28 2025-09-29 Basf Se Anvendelse af forbindelser af strobilurintypen til bekæmpelse af fytopatogene svampe, der indeholder en f129l-aminosyresubstitution i det mitokondrielle cytokrom b-protein, der giver resistens over for qo-hæmmere (i)
EP3903582A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ii
EP3903583A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iii
KR20230005262A (ko) 2020-04-28 2023-01-09 바스프 에스이 Qo 억제제 iii 에 내성을 부여하는 미토콘드리아 시토크롬 b 단백질에서 아미노산 치환 f129l 을 함유하는 식물병원성 진균을 퇴치하기 위한 스트로빌루린 유형 화합물의 용도
US20230212164A1 (en) 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
EP3970494A1 (en) 2020-09-21 2022-03-23 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
US20230357152A1 (en) 2020-08-11 2023-11-09 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
KR20230137286A (ko) 2020-09-11 2023-10-04 미라티 테라퓨틱스, 인크. Kras g12c 억제제의 결정 형태
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4214204A1 (en) * 2020-09-18 2023-07-26 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN114539245A (zh) * 2020-11-26 2022-05-27 上海翰森生物医药科技有限公司 含嘧啶并环类衍生物调节剂、其制备方法和应用
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
US11999753B2 (en) 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
GEP20257811B (en) 2021-01-19 2025-10-27 Lupin Ltd Pharmaceutical combinations of sos1 inhibitors
WO2022156792A1 (en) * 2021-01-25 2022-07-28 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as sos1 inhibitors
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
US20240109887A1 (en) * 2021-03-02 2024-04-04 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted bicyclic aza-heterocycles as sos1 inhibitors
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
US20240197888A1 (en) * 2021-03-17 2024-06-20 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
US20220324862A1 (en) * 2021-03-31 2022-10-13 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
US20240277714A1 (en) * 2021-04-09 2024-08-22 Revolution Medicines, Inc. Use of sos1 inhibitors with ras inhibitors to treat cancers
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2022266248A1 (en) * 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4358963A4 (en) 2021-06-21 2025-04-02 Mirati Therapeutics, Inc. SOS1 INHIBITORS
WO2023041049A1 (zh) 2021-09-17 2023-03-23 江苏先声药业有限公司 作为sos1抑制剂的杂环化合物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023067546A1 (en) * 2021-10-21 2023-04-27 Satyarx Pharma Innovations Pvt Ltd Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors
WO2023072670A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors x
WO2023072671A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ix
KR20240128852A (ko) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024543976A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
US20250129095A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543975A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
WO2023098825A1 (zh) * 2021-12-02 2023-06-08 勤浩医药（苏州）有限公司 Sos1抑制剂、包含其的药物组合物及其用途
US20250011304A1 (en) 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
US20250154147A1 (en) 2022-01-14 2025-05-15 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
KR20230121208A (ko) 2022-02-10 2023-08-18 (주)파로스아이바이오 Sos1 억제제 및 이의 유도체
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
KR20240167633A (ko) 2022-03-31 2024-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료용 약학 조성물
KR20250004810A (ko) 2022-04-20 2025-01-08 컴쿼트 바이오사이언시즈 인크. 대환식 헤테로환 및 이의 용도
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4573095A1 (en) 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
EP4600243A2 (en) * 2022-10-07 2025-08-13 Jeil Pharmaceutical Co., Ltd. Novel bicyclic heterocyclyl compounds and use thereof
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
US20240208909A1 (en) * 2022-12-02 2024-06-27 Accutar Biotechnology Inc. Substituted quinoline derivatives having sos1 inhibition activities and uses thereof
DE102024102431A1 (de) 2023-02-01 2024-08-01 Deutsche Institute für Textil- und Faserforschung Denkendorf Stiftung des öffentlichen Rechts Amin-funktionalisiertes Cellulosematerial, Verfahren zu dessen Herstellung und Verwendung als CO2-Adsorber
CN120813358A (zh) 2023-04-06 2025-10-17 卫材R&D管理有限公司 用于治疗肿瘤的药物组合物
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202446388A (zh) 2023-04-14 2024-12-01 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025059046A1 (en) 2023-09-11 2025-03-20 Kumquat Biosciences Inc. Sos1 inhibitors for use in the treatment of philadelphia chromosome positive blood cancers
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025090808A1 (en) 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer
WO2025090812A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Methods of modulating cell proliferation
WO2025090810A1 (en) 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1
WO2025210042A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) * 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6174899B1 (en) 1998-05-14 2001-01-16 Morton Shulman Orally administered analgesic composition comprising myfadol
US7291725B2 (en) * 2002-06-26 2007-11-06 Chiron Corporation Sos1 inhibitors
CA2680775A1 (en) 2007-03-23 2008-10-02 F. Hoffmann-La Roche Ag Aza-pyridopyrimidinone derivatives
WO2010019637A1 (en) 2008-08-12 2010-02-18 Smithkline Beecham Corporation Chemical compounds
US20110230499A1 (en) 2008-11-28 2011-09-22 Novartis Ag Hsp90 inhibitors for therapeutic treatment
HRP20160190T1 (hr) 2008-12-12 2016-03-25 Boehringer Ingelheim Int Protutijela anti-igf
ES2658290T3 (es) 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa
EP2649016B1 (en) 2010-12-06 2020-06-10 Pall Corporation Continuous processing methods for biological products
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
UA114906C2 (uk) 2012-03-14 2017-08-28 Люпін Лімітед Гетероциклільні сполуки як інгібітори мек
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
EP3601267A1 (en) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
BR112021024532A2 (pt) 2019-06-19 2022-05-24 Boehringer Ingelheim Int Terapia combinada anticâncer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) * 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JU HOU: "Design, synthesis, anti-tumor activity, and molecular modeling of", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
CN116425742A (zh) * 2019-11-08 2023-07-14 锐新医药公司 双环杂芳基化合物及其用途
CN114746411A (zh) * 2019-11-29 2022-07-12 印度鲁宾有限公司 取代的三环化合物
CN114746411B (zh) * 2019-11-29 2024-06-25 印度鲁宾有限公司 取代的三环化合物
CN115605476A (zh) * 2019-12-27 2023-01-13 鲁宾有限公司（In） 取代的三环化合物
CN115244058A (zh) * 2020-04-08 2022-10-25 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2021203768A1 (zh) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
CN115461342A (zh) * 2020-05-09 2022-12-09 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
CN115697994A (zh) * 2020-06-10 2023-02-03 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
WO2021249519A1 (zh) * 2020-06-11 2021-12-16 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113801114A (zh) * 2020-06-11 2021-12-17 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115605479B (zh) * 2020-06-11 2024-05-14 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN115605479A (zh) * 2020-06-11 2023-01-13 江苏恒瑞医药股份有限公司（Cn） 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113801114B (zh) * 2020-06-11 2022-11-18 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115942936A (zh) * 2020-06-24 2023-04-07 勃林格殷格翰国际有限公司 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
CN113912608A (zh) * 2020-07-10 2022-01-11 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022017339A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
CN116234807A (zh) * 2020-07-24 2023-06-06 南京明德新药研发有限公司 喹唑啉类化合物
CN116234807B (zh) * 2020-07-24 2025-10-14 南京明德新药研发有限公司 喹唑啉类化合物
WO2022017519A1 (zh) * 2020-07-24 2022-01-27 南京明德新药研发有限公司 喹唑啉类化合物
CN116194446A (zh) * 2020-08-06 2023-05-30 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022028506A1 (zh) * 2020-08-06 2022-02-10 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN112174891B (zh) * 2020-11-02 2022-02-01 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
CN112174891A (zh) * 2020-11-02 2021-01-05 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
CN114524810A (zh) * 2020-11-21 2022-05-24 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2022105921A1 (zh) * 2020-11-21 2022-05-27 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114524810B (zh) * 2020-11-21 2023-12-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN116568681A (zh) * 2020-12-07 2023-08-08 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022121813A1 (zh) * 2020-12-07 2022-06-16 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CN114621231A (zh) * 2020-12-14 2022-06-14 杭州中美华东制药有限公司 一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
CN116648250A (zh) * 2020-12-22 2023-08-25 韩美药品株式会社 作为sos1抑制剂的新型喹唑啉衍生物及其用途
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685531A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685487A (zh) * 2020-12-27 2022-07-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN116249529A (zh) * 2020-12-30 2023-06-09 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
WO2022143533A1 (zh) * 2020-12-30 2022-07-07 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
CN116249529B (zh) * 2020-12-30 2025-06-06 康百达（四川）生物医药科技有限公司 喹唑啉衍生物及其在医药上的应用
CN114685488A (zh) * 2020-12-31 2022-07-01 南京圣和药业股份有限公司 作为sos1抑制剂的化合物及其应用
WO2022148442A1 (zh) * 2021-01-07 2022-07-14 武汉人福创新药物研发中心有限公司 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
CN116546985A (zh) * 2021-01-28 2023-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
CN114436976A (zh) * 2021-01-29 2022-05-06 石药集团中奇制药技术（石家庄）有限公司 一种新型喹唑啉类衍生物及其制备和应用
WO2022166592A1 (zh) * 2021-02-02 2022-08-11 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
WO2022166974A1 (zh) * 2021-02-08 2022-08-11 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN116669738A (zh) * 2021-02-09 2023-08-29 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
WO2022170802A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
CN116568689A (zh) * 2021-02-09 2023-08-08 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
CN116568689B (zh) * 2021-02-09 2025-07-11 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
WO2022170917A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN117295732A (zh) * 2021-02-10 2023-12-26 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022171184A1 (zh) * 2021-02-10 2022-08-18 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022171118A1 (zh) * 2021-02-10 2022-08-18 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN114907284A (zh) * 2021-02-10 2022-08-16 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2022184116A1 (zh) * 2021-03-05 2022-09-09 江苏先声药业有限公司 新型sos1抑制剂及其制备方法和应用
WO2022188819A1 (zh) * 2021-03-09 2022-09-15 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
CN115043817A (zh) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
WO2022199635A1 (zh) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 苄氨基喹唑啉类衍生物
WO2022199670A1 (zh) * 2021-03-26 2022-09-29 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
CN116917286A (zh) * 2021-03-26 2023-10-20 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
CN115215847B (zh) * 2021-04-16 2025-05-13 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
CN115215847A (zh) * 2021-04-16 2022-10-21 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
CN115232108B (zh) * 2021-04-23 2025-04-18 领泰生物医药(绍兴)有限公司 Sos1降解剂及其制备方法和应用
WO2022258057A1 (en) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Compounds as anticancer agents
WO2022262691A1 (en) * 2021-06-17 2022-12-22 Beijing Innocare Pharma Tech Co., Ltd. Heterocyclic compounds as sos1 inhibitors
WO2022268209A1 (zh) * 2021-06-24 2022-12-29 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途
CN115677699A (zh) * 2021-07-23 2023-02-03 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2023001229A1 (zh) * 2021-07-23 2023-01-26 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途
CN115677824A (zh) * 2021-07-26 2023-02-03 中国科学院上海药物研究所 可诱导sos1蛋白质降解的化合物、制备方法和用途
CN115677601B (zh) * 2021-07-29 2025-06-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115677601A (zh) * 2021-07-29 2023-02-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2023030216A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途
CN115417868B (zh) * 2021-09-13 2024-04-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN115417868A (zh) * 2021-09-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN115246841A (zh) * 2021-09-14 2022-10-28 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115246841B (zh) * 2021-09-14 2024-02-09 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115536660B (zh) * 2021-11-04 2025-09-02 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN116143708A (zh) * 2021-11-21 2023-05-23 四川汇宇制药股份有限公司 一种多取代苯并氮杂芳基衍生物及其用途
WO2023109929A1 (zh) 2021-12-17 2023-06-22 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2023138526A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 含烯丙基的甲基吡啶并嘧啶化合物的晶型
WO2023143147A1 (zh) * 2022-01-28 2023-08-03 上海优理惠生医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN116768858A (zh) * 2022-03-15 2023-09-19 杭州中美华东制药有限公司 具有kras-sos1抑制或降解活性的嵌合化合物及其用途
CN117024404A (zh) * 2022-05-10 2023-11-10 四川汇宇制药股份有限公司 苯并吡啶衍生物及其用途
WO2023241414A1 (zh) * 2022-06-13 2023-12-21 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物
CN119894894A (zh) * 2022-09-23 2025-04-25 无锡瓴方生物医药科技有限公司 喹唑啉类化合物的晶型及其制备方法
WO2024061353A1 (zh) * 2022-09-23 2024-03-28 南京明德新药研发有限公司 喹唑啉类化合物的晶型及其制备方法
CN119894894B (zh) * 2022-09-23 2025-12-05 无锡瓴方生物医药科技有限公司 喹唑啉类化合物的晶型及其制备方法
CN119907792A (zh) * 2022-10-21 2025-04-29 领泰生物医药(绍兴)有限公司 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途
CN119907792B (en) * 2022-10-21 2025-12-09 领泰生物医药(绍兴)有限公司 Benzyl or thiophene methylene substituted aminoquinazoline derivatives and their use as SOS1 degradants
CN116444447B (zh) * 2023-06-19 2023-09-22 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用
CN116444447A (zh) * 2023-06-19 2023-07-18 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用

Also Published As

Publication number Publication date
US12053473B2 (en) 2024-08-06
JP2020504742A (ja) 2020-02-13
US10898487B2 (en) 2021-01-26
JP7219218B2 (ja) 2023-02-07
EP3558979A1 (en) 2019-10-30
US20210177851A1 (en) 2021-06-17
EP3558979B1 (en) 2021-02-17
EP3878850A1 (en) 2021-09-15
WO2018115380A1 (en) 2018-06-28
US20190358230A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CN110167928A (zh) 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
JP7189956B2 (ja) Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
CN115353509B (zh) 含氮杂芳类衍生物调节剂、其制备方法和应用
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
US20250129096A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20200119824A (ko) 축합 고리 화합물
KR20220024191A (ko) 항암제 조합 요법
EP4605399A1 (en) Oxazepine compounds comprising a 6-aza moiety and uses thereof
KR20110089418A (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
US20230372527A1 (en) Combination of antibody-drug conjugate and parp1 selective inhibitor
KR20180052623A (ko) 신규 화합물
AU2018234985B2 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
TW202128693A (zh) 含吡唑多環類衍生物抑制劑、其製備方法和應用
KR102691777B1 (ko) 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
HK40097417A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
TW202136259A (zh) 聯苯類衍生物抑制劑及其製備方法和應用
HK40039222B (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40011175B (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
HK40011175A (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination